Pharma Tech

GSK licenses HUTCHMED’s solid tumour conjugate in up to $1.3bn deal

Sep 3, 2026, 10:57 AM

Read Full Article → GSK licenses HUTCHMED’s solid tumour conjugate in up to $1.3bn deal

Translate article text

Choose a language and wait for the translated text.

HMPL-A830 is an antibody-targeted therapy conjugate (ATTC) that selectively delivers a therapeutic drug to cancer cells, while sparing healthy tissue.